Drug Development

Phase I trial of C. difficile vaccine commences

Published in Biotech Business Week, August 22nd, 2005

Acambis plc (ACM, ACAM) announced that it started a phase I clinical trial of its investigational vaccine against Clostridium difficile (C. difficile).

C. difficile infection, which is characterized by diarrhea and colitis, represents one of the most common hospital-acquired infections around the world. A new virulent strain of C. difficile has also emerged, causing sharp increases in the number of infections and deaths associated with the infection in a number of countries including the U.K., Canada, the Netherlands and the U.S.

The phase I trial is designed to obtain information on the safety, tolerability and immunogenicity of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2005-08-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry